drugset / Trial / NCT04643600

The Effect of Orally Administered L- Arginine on Quadriceps Strenght in Healthy Smokers

NCT04643600

Phase 4 Unknown 163 enrolled Goranka Radmilović
RandomizedCrossoverSingle-blindPrevention

Summary

The study will investigate changes in certain locomotor parameters as early predictors of disease in smokers who are prone to develop chronic obstructive pulmonary disease (COPD).

Timeline

Start
2019-03-01
Primary completion
2022-02-15
Completion
2022-02-17

Drugs

EvaluationDrugModalityDoseRoute
Comparator L-arginine Small molecule 500 mg Oral

Indications

No indication recorded.